RxDoctor Payments Data

James Kim, MD

Medical Oncology · Youngstown, OHNPI 1972036341

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $614 of the $755 with a category attached, or 81.3%. It is spread thinly across 8 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $607, 5.6 times the $107 reported in 2020. That places this record below the midpoint for medical oncology clinicians in OH, where the typical reported total is $2,659.

$755in general payments, 2019–2025

Across 11 payments — averaging $68.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$145
  • Jazz Pharmaceuticals Inc.$126
  • Johnson & Johnson$110
  • Beone Medicines USA, Inc.$110
  • Takeda Pharmaceuticals U.S.A., Inc.$107
  • Seagen Inc.$100
  • plus $57 from 2 others
$152,633in research payments, 2019–2025

Across 14 payments — averaging $10,902 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$95K
  • Spectrum Pharmaceuticals Inc.$58K

What the payments were for

  • Food & beverage$61481%
  • Education$14119%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$755 in reported general payments places this provider in the 30th percentile of 157 medical oncology providers in Ohio.

See all medical oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$98,932
Medicare patients
321
Services billed
1,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib44$685,694
JakafiRuxolitinib Phosphate14$226,878
SprycelDasatinib12$178,429
EliquisApixaban24$14,668
Anastrozole245$3,741
Exemestane18$3,545
Prochlorperazine Maleate98$1,799
Tamoxifen Citrate61$1,667
Letrozole52$1,374
Ondansetron Hcl51$1,051
Dexamethasone38$913
SynthroidLevothyroxine Sodium20$888
Hydroxyurea40$641
Duloxetine Hcl40$596
Ondansetron OdtOndansetron38$469

Paid to pharmacies, not to this prescriber.

Other medical oncology in Youngstown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →